Are Sulfonylureas Passé?

Current Diabetes Reports

Volumn 6, Issue 5, 2006, Pages 373-377

  Green, Jennifer B ^a   Feinglos, Mark N ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; INSULIN SENSITIZING AGENT; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE;

BODY WEIGHT DISORDER; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; DIABETES CONTROL; DRUG MECHANISM; DRUG TOLERABILITY; HEALTH CARE COST; HEART DISEASE; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOGLYCEMIA; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; PRODUCT DEVELOPMENT; REVIEW; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; SULFONYLUREA COMPOUNDS; WEIGHT GAIN;

EID: 34347403804     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-006-0008-9     Document Type: Review

References (31)

1. CDC's Diabetes Program: Data & Trends - Prevalence of Diabetes. http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm. Accessed June 30, 2006.
2. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131:281-303.
3. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group [no authors listed]. Diabetes 1995, 44:1249-1258.
4. Rendell M: The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004, 64:1339-1358.
5. Riddle MC: Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulin, and combinations. Endocrinol Metab Clin North Am 2005, 34:77-98.
6. Krentz AJ, Bailey CJ: Oral antidiabetic agents. Drugs 2005, 65:385-411.
7. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002, 287:360-372.
8. Morello CM, Edelman SV: Exenatide. Practical Diabetology 2006, 25:6-18.
9. Holst JJ: Glucagon-like peptide-1: from extract to agent. Diabetologia 2006, 49:253-260.
10. Mest HJ, Mentlein R: Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005, 48:616-620.
11. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837-853.
12. Putnam WS, Andersen DK, Jones RS, et al.: Selective Potentiation of insulin-mediated glucose disposal in normal dogs by the sulfonylurea glipizide. J Clin Invest 1981, 67:1016-1023.
13. Bell DS: Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004, 26:1714-1727.
14. Burge MR, Sood V, Sobhy TA, et al.: Sulphonylurea-induced hypoglycemia in type 2 diabetes mellitus: a review. Diabetes Obes Metab 1999, 1:199-206.
15. Rosak C: The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. J Diabetes Complications 2002, 16:123-132.
16. Sonnenberg GE, Garg DC, Weidler DJ, et al.: Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother 1997, 31:671-676.
17. Simonson DC, Kourides IA, Feinglos MN, et al.: Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 1997, 20:597-606.
18. Davis SN: The role of glimepiride in the effective management of type 2 diabetes. J Diabetes Complications 2004, 18:367-376.
19. Turner RC, Cull CA, Frighi V, et al.: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012.
20. Goldner MG, Knatterud GL, Prout TE: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971, 218:1400-1410.
21. Rao SV, Bethel MA, Feinglos MN: Treatment of diabetes mellitus: Implications of the use of oral agents. Am Heart J 1999, 138:334-337.
22. American diabetes association policy statement: the UGDP controversy [no authors listed]. Diabetes Care 1979, 2:1-3.
23. Garratt KN, Brady PA, Hassinger NL, et al.: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998, 33:119-124.
24. Meier JJ, Gallwitz B, Schmidt WE, et al.: Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004, 90:9-12.
25. Cleveland JC, Meldrum DR, Cain BS, et al.: Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Circulation 1997, 96:29-32.
26. Lee TM, Chou TF: Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003, 88:531-537.
27. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854-865.
28. Charpentier G: Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev 2002, 18:S70-S76.
29. Buse JB, Fineman MS, Henry RR, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
30. Baggio LL, Drucker DJ: Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 2006, 57:265-281.
31. Riddle MC: Editorial: sulfonylureas differ in effects on ischemic preconditioning - is it time to retire glyburide? J Clin Endocrinol Metab 2003, 88:528-530.